Pharmafile Logo

News:

August 10, 2021 | Medtech 

MedTech Qualitative Specialist joins Research Partnership

Research Partnership is delighted to announce that Scott Kirklin has joined the company as a Qualitative Research Director. Based in the US, Scott has over 22 years of qualitative market research and account management experience in MedTech. He has worked with most of the Top 25 firms in the healthcare industry and is recognised as a resourceful moderator and qualitative expert in areas such as diagnostics, sophisticated consumables, user-centric technologies/delivery systems and system-wide software solutions.

Read more here: https://bit.ly/37yrDJC

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Nutraceuticals: Rich in Potential

Published in eyeforpharma October 2016 by Marc Yates

Case Study: Qualitative research with payers in low and middle income countries

Our client wanted to understand in detail the usage decision drivers, triggers and processes for a high-cost innovative Acute Heart Failure (AHF) drug used in the acute emergency setting in...

Case study: Leveraging Market Research Data to Inform Healthcare Providers and the Community

Our client wanted to understand why uptake of HPV vaccination in the Asia-Pacific region was limited.  In order to help increase uptake, they wanted to publish the market research findings...

Towards a culture of evaluation and evidence-based decision making in global health

Reflections on THET Conference 2016: Evidence, Effectiveness & Impact

Research Partnership has published a new Living with Ulcerative Colitis (UC) market report for 2016

Ulcerative Colitis (UC) is a progressive and debilitating disease which affects between 2.5 to 3 million people in Europe. Living with UC is a quantitative study conducted online amongst 325 patients, including...

The Internet of Things

Evolution from man to machine

Therapy Watch expands its oncology portfolio

This month Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). Therapy Watch SCCHN is part of a wider portfolio...

Time for a new language for asthma?

Despite the global advances made in the treatment for asthma, many studies have shown that asthma remains uncontrolled for a large proportion of patients, when assessed according to international guidelines....

Evaluating the impact of your medical congress presence…more cost effectively

Organising a company’s presence, not just logistically, but in terms of delivering key information, data and messages, is a massive part of some people’s workload at this time of year....